News

Reblozyl is an erythroid maturation agent, which was co-developed by Celgene and Acceleron Pharma. According to Celgene, the FDA-approved drug is a new class of therapy that has

The OLYMPUS trial compared roxadustat to placebo while the ROCKIES trial compared roxadustat to epoetin alfa. The results were presented today during two oral sessions at the American

The company has submitted marketing authorisation applications (MAAs) to the EMA to prevent Ebola Virus Disease (EVD) caused by Zaire ebolavirus species. Janssen has submitted two MAAs in

Takeda’s dengue vaccine candidate demonstrated protection against virologically-confirmed dengue (VCD), the trial primary endpoint, in children ages four to 16 years. Vaccine efficacy (VE) was 80.2% (95% confidence

SB11, a biosimilar candidate referencing LUCENTIS (ranibizumab), is undergoing phase 3 clinical trial, while SB15, a biosimilar candidate referencing EYLEAiii (aflibercept), is in pre-clinical development. In addition, the

Mechanistic data on AXA4010 will be presented at the American Society of Hematology’s (ASH) 2019 Annual Meeting. Additionally, the company has initiated enrollment of subjects with sickle cell

Both firms will also sign a five-year research agreement to use Regeneron’s VelociSuite technologies to jointly design and validate Vesicular Stomatitis Virus (VSV)-based oncolytic virus treatments. Under the

The companies aim to empower Cyclica’s patented, evolutionary algorithm with new design options based on the 73,000 Enamine’s in-stock building blocks and 171 thoroughly validated synthesis procedures. The

The company, founded in 2018 by veteran biotechnology leaders, has a unique and potentially broad solution for the central problem of cancer research – targeted killing of tumor